![]()
This week’s selections from Life Science Leader offer encouraging signs of early successes in hard-to-treat conditions, or at least a roadmap to get there. From a regulatory perspective, FDA created a flexible framework that could lead to more “Baby KJ” success stories — cures for genetic ultra rare diseases. Experts at Morrison Foerster examined the framework and its implications for drug developers.
On the Business of Biotech, William Ho, CEO, IN8bio, describes running on funding fumes before rebuilding the runway for IN8bio’s gamma delta T cell therapies in solid tumors like glioblastoma, a notoriously difficult target.
And finally, Tom Wells reminds us that no matter how innovative a new therapy might be, emerging biotechs focused on R&D can miss the opportunity to help patients by paying too little attention to procurement. Often overlooked as a functional mechanism, the strategic importance of procurement is hard to overstate.
Check out a curated selection from our partners, below, and thanks as always for reading.
Ben Comer
Chief Editor, Life Science Leader
This week’s selections from Life Science Leader offer encouraging signs of early successes in hard-to-treat conditions, or at least a roadmap to get there. From a regulatory perspective, FDA created a flexible framework that could lead to more “Baby KJ” success stories — cures for genetic ultra rare diseases. 
